Published in Gene Therapy Weekly, March 4th, 2010
"We, therefore, wanted to investigate whether this is the case in the fine experimental model of atherosclerosis: apolipoprotein E (apoE)knockout mice. Nebivolol attenuated atherogenesis, measured both by ''en face'' method (9.23 +/- 1.8% vs. 14.6 +/- 2.1%) and ''cross-section'' method (63125 +/- 8455 mu m(2) vs. 91416 +/- 8357 m(2))," wrote K. Kus and colleagues, Jagiellonian University.
...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2010-03-04)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.